What question did this study set out to answer?

This research aims to investigate the anti-cancer effects of tangeretin on HER2-positive breast cancer cells.

Tangeretin suppresses HER2-driven breast cancer via PI3K/AKT/mTOR inhibition and caspase-dependent apoptosis

View Full Paper

Ask AI

Bookmark

Authors

In vitro study reveals tangeretin suppresses HER2-driven breast cancer, indicating a promising anti-cancer strategy.

This research aims to investigate the anti-cancer effects of tangeretin on HER2-positive breast cancer cells.
Evaluated the cytotoxicity of tangeretin in various breast cancer cell lines including SKBR3 and MCF-7.
Assessed apoptosis through staining, DNA laddering, and caspase activity measurements.
Examined cell cycle effects via flow cytometry to measure G₂/M phase arrest.
Analyzed the downstream effects on key signaling proteins in the PI3K/AKT/mTOR pathway.
Tangeretin exhibited significant cytotoxicity with IC₅₀ values of 19.5 µM for SKBR3 and 36.2 µM for MCF-7 cells.
Induced late apoptosis in 50.6% of SKBR3 cells with caspase-3/7 and caspase-9 activation.
Reduced clonogenic survival in SKBR3 and MCF-7 cells (51.4% and 78.1% colonies, respectively).
Suppressed AKT and downstream signaling, with a comparable effect to the drug MK-2206.

Reddy et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark